The Readout Loud

324 Episodes

1. 242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score

   Published: 19/01/2023
2. 241: #JPM23 in review, the year ahead, & the merits of Miami

   Published: 12/01/2023
3. 240: #JPM23, the future of Alzheimer's, & rising Covid variants

   Published: 05/01/2023
4. 239: 2022 in review, CEO indictments, & the year ahead

   Published: 22/12/2022
5. 238: Leaky health data, ASH22, & what it takes to get booed by your peers

   Published: 15/12/2022
6. 237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing

   Published: 08/12/2022
7. 236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

   Published: 01/12/2022
8. 235: LIVE from the STAT Summit

   Published: 17/11/2022
9. 234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy

   Published: 10/11/2022
10. 233: How the biotech revolution could come apart at the seams

    Published: 03/11/2022
11. 232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

    Published: 27/10/2022
12. 231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market

    Published: 20/10/2022
13. 230: BIO's messy transition, mRNA's future, & Biogen's next CEO

    Published: 13/10/2022
14. 229: Nobels for science, biotech dealmaking, & a friendly FTC

    Published: 06/10/2022
15. 228: A surprise success in Alzheimer's and how FDA history seeded modern controversy

    Published: 29/09/2022
16. 227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0

    Published: 22/09/2022
17. 226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred

    Published: 15/09/2022
18. 225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

    Published: 08/09/2022
19. 224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

    Published: 01/09/2022
20. 223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO

    Published: 25/08/2022